Clinical trial · Interventional
99mTc-CNDG SPECT/CT in Brain Tumors
Application of 99mTc-CNDG SPECT/CT Imaging in the Diagnosis of Brain Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are: 1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG? 2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type? Participants will: Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intracranial Tumor | Intracranial Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 99mTc-CNDG SPECT/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- intracranial tumor
- interventionNames
- Diagnostic Test: 99mTc-CNDG SPECT/CT
Primary outcomes (1)
- measure
- SUVmax
- timeFrame
- 1month
- description
- 1\. Diagnostic consistency evaluation of 99mTc-CNDG and 18F-FDG; 2.Correlation of SUV value of 99mTc-CNDGwith tumor type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with clinical diagnosis of brain tumor; * Be at least 18 years old; * The final pathological results could be obtained by surgery or biopsy; * Informed consent and the ability to be followed up; * Those who did not meet the exclusion criteria. Exclusion Criteria: * Insulin-dependent diabetes mellitus or fasting blood glucose \>7 mmol/L before 99mTc-CNDG injection; * Severe liver or kidney disease (serum creatinine level \>3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal); * Severe hypersensitivity or hypersensitivity to radiocontrast agents; * Claustrophobia (inability to undergo SPECT/CT or PET/CT scans); * Patients receiving radiotherapy and chemotherapy; * Being pregnant or breastfeeding.
References
Publications (0)
Data not yet available